Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

BioAtla Q1 2024 GAAP EPS $(0.48) Beats $(0.54) Estimate

Author: Benzinga Newsdesk | May 14, 2024 04:23pm
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11.11 percent. This is a 17.24 percent increase over losses of $(0.58) per share from the same period last year.

Posted In: BCAB

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist